SUMMARY Calcium channel blockade provides a logical approach to the treatment of pulmonary hypertension because these drugs exert direct vasodilator effects in the highly constricted pulmonary circulation. To determine the effectiveness of verapanil in the treatment of primary pulmonary hypertension the haemodynamic effects of the drug were evaluated in seven patients with this disorder; 10 mg was given intravenously to six patients and 120 mg orally to one patient. Verapamil produced a 20% decline in pulmonary vascular resistance and a 27% decrease in mean pulmonary arterial pressure without significant changes in systemic vascular resistance. One patient who received verapanil 480 mg orally daily for three months showed sustained haemodynamic and clinical improvement. Concomitant with its beneficial effects on the pulmonary circulation, however, verapamil produced a pronounced decrease in right ventricular stroke work index (42%) and increase in right ventricular filling pressure (50%), indicating a direct depressant effect of the drug on right ventricular function. In one patient these cardiodepressant effects were sufficiently pronounced to produce severe hypotension and cardiac arrest.
Because pulmonary vasoconstriction has been thought to play an important contributory role in the pathophysiology of primary pulmonary hypertension' 3 several vasodilator drugs have been used in patients with this disorder in an attempt to reduce pulmonary artery pressure and pulmonary vascular resistance. 4 Although occasionally haemodynamic and clinical benefit have followed treatment with various vasodilator agents,4-7 there remains no satisfactory pharmacological approach to the management of these patients. The major limitation to presently available drugs is that most agents have potent systemic vasodilator effects that exceed the magnitude of their effects on the pulmonary circulation; these systemic effects may result in severe hypotension before any appreciable improvement in pulmonary haemodynamic indices occurs.4 8 9 Requests for reprints to Dr Milton Packer, Division of Cardiology, Mount Sinai Medical Center, 1 Gustave Levy Place, New York, New York 10029, USA.
Accepted for publicaton 1 March 1984 Because calcium appears to play a critical role in vascular smooth muscle contraction'0" calcium channel blockade with nifedipine and verapamil provides a logical approach to the treatment of a variety of conditions characterised by abnormal regional vasoconstriction.'2-15 Calcium channel antagonists appear to exert preferential effects in regional vascular systems that are highly constricted, particularly in the coronary, cerebral, and pulmonary circulations'0 .6; hence, these drugs have proved useful in the treatment of vasospastic angina and in subarachnoid haemorrhagel2-14; however, there are only preliminary data on the usefulness of calcium channel blockade in pulmonary vasoconstrictive states. Nifedipine attenuates the vasoconstrictor response to hypoxia in several experimental preparations '7 18 and in patients with acute respiratory failure,'9 and several case studies have reported the benefits of short and long term nifedipine treatment in patients with primary pulmonary hypertension. [20] [21] [22] [23] [24] In contrast, although verapamil also attenuates hypoxic pulmonary vasoconstrictionl8 25 26 there are few data on its effective-Verapamil for pulmonary hypertension ness in hypoxic or primary pulmonary hypertension.7 The therapeutic application of verapamil in the treatment of abnormal pulmonary vasoconstriction has theoretical appeal since the drug exerts less pronounced effects on the systemic circulation than does nifedipinell and thus may produce less hypotension than do drugs that have pronounced systemic vasodilator actions.
In the present study we evaluated the haemodynamic and clinical responses to verapamil in seven patients with primary pulmonary hypertension, one of whom was treated with the drug for three months and underwent repeat haemodynamic evaluation.
Patients and methods

STUDY POPULATION
We studied seven patients with primary pulmonary hypertension (five women, two men; age range 28-64 (mean 48) years). The diagnosis was established in all patients by right heart catheterisation, which confirmed the pronounced increase in pulmonary artery pressures (mean pulmonary artery pressure >30 mm Hg) and a normal pulmonary capillary wedge pressure (<15 mm Hg After completion of the intravenous study, long term treatment with oral verapamil (480 mg daily) was started in one patient, who underwent repeat haemodynamic evaluation after three months; at that time, the haemodynamic effects of verapamil were assessed at peak drug effect, and 48 hours after drug withdrawal. This patient received no other medications during this period.
DATA ANALYSIS
Mean systemic and pulmonary artery pressures were determined by electronic filtration. Derived haemodynamic variables were calculated according to the following formulae: cardiac index (CI) = CO/body surface area (1/minim2); stroke volume index (SVI) = CI/HR (ml/beat/m2); RV stroke work index (RVSWI) = SVIxO-0136x(MPAP-MRAP) ( (1 SD) .
Results
HAEMODYNAMIC EFFECTS
The individual haemodynamic responses to verapamil in the seven patients with primary pulmonary hypertension are shown in Table 1 . Verapamil produced a decrease in pulmonary vascular resistance in each patient in our study (range 10-32%); overall, mean pulmonary vascular resistance declined from 1344 to 1078 dyn s cm-5 (p<0025). In contrast, the small decrease in systemic vascular resistance after verapamil (1619 to 1469 dyn s cm-5) was not significant, and the decline in pulmonary vascular resistance exceeded the changes seen in the systemic circulation in all but one patient. The fall in pulmonary vascular resistance after verapamil resulted primarily from a pronounced decrease in mean pulmonary artery pressure with the drug (63-3 to 46-1 mm Hg, p<0-05) since there was little overall change in cardiac index. Part of the lack of improvement in cardiac index occurred because heart rate decreased substantially in some patients (> 10 beats/min in three patients), but the overall fall in heart rate (-7 beats/min) was not significant, and thus, there were no overall changes in stroke volume index (24.4 to 23.7 ml/beat/M2). Verapamil produced a significant increase in mean right atrial pressure (11.4 to 17.1 mm Hg, p<0-01), however, and a decrease in right ventricular stroke work index (16-3 to 9.5 g M/M2, p<0.01).
Although there were no overall changes in cardiac index, two patients had a pronounced decrease in cardiac index after verapamil (-0-82 and -0.58 l/minI m2), and these two patients also showed the most pronounced changes in mean pulmonary artery pressure (-22 and - 30 Lastly, long term nifedipine treatment may be accompanied by peripheral oedema3l; such fluid retention may confuse the clinical picture of right heart failure, which so commonly complicates the course of chronic pulmonary hypertension.
Verapamil may provide a therapeutic alternative to nifedipine for the management of pulmonary hypertension. Compared with nifedipine the drug appears to exert less pronounced effects on systemic vascular resistance," neutralises the reflex increase in sympathetic tone resulting from systemic vasodilatation,28 and rarely produces peripheral oedema.'3 In a similar way to nifedipine, verapamil attenuates acute hypoxic pulmonary vasoconstriction in experimental studies'8 25 26 and may lessen the magnitude of secondary right ventricular hypertrophy after chronic hypoxia.32 33 There are, however, few reports of the use of verapamil in hypoxic pulmonary hypertension in man. Furthermore, preliminary work by Landmark and colleagues27 with verapamil in nine patients with primary pulmonary hypertension has largely been unfavourable. These investigators found that the injection of 0 15 mg/kg of verapamil directly into the pulmonary artery produced only small decreases in pulmonary artery pressure and no change in pulmonary vascular resistance or cardiac output. Although an occasional patient showed notable pulmonary vasodilatation, others had pronounced decreases in cardiac output and right ventricular stroke work, one of whom had severe dyspnoea and hypotension after drug administration. Because of the lack of appreciable pulmonary vasodilator effects, Landmark et Verapainil for pulmonary hyperunsion 110 decreases in mean pulmonary artery pressure. Long term treatment with oral verapamil in one patient produced notable haemodynamic and symptomatic improvement that was sustained for three months. Unfortunately, despite these benefits, cardiac index failed to increase in most of our patients despite the decrease in resistance to right ventricular systolic ejection because verapamil treatment was accompanied by decreases in right ventricular stroke work and increases in right ventricular filling pressure; these haemodynamic responses indicated that the drug exerted a direct negative inotropic effect on right ventricular function, independent of its pulmonary vasodilator action. This is consistent with the known cardiodepressant effects of verapamil that result from its ability to block transmembrane calcium transport in the myocardium. 34 19 and appear to be secondary to the pronounced systemic vasodilator effects that may occasionally accompany treatment (and produce hypotension) and to the dilatation of transpulmonary shunts (which may produce hypoxaemia).7 8 In conclusion, despite its preferential vasodilator Packer, Medina, Yushak, Wiener effects on the pulmonary circulation, we do not recommend verapamil for treating patients with primary pulmonary hypertension. Although an occasional patient's condition may improve during short and long term treatment with the drug, most patients will experience major depressant effects on right ventricular performance, and this may have serious cardiovascular consequences. Calcium channel blockade may be a useful approach to the management of primary pulmonary hypertension, but its application requires the development of a drug with selective pulmonary vasodilator effects and without appreciable negative inotropic action. Since verapamil may be given to patients with chronic pulmonary hypertension for the treatment of atrial tachycardias (in patients with severe mitral stenosis) or for the treatment of exertional angina (in patients with chronic obstructive lung disease), we advise caution with its use in any patient with severe right ventricular dysfunction.
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